Teacher Retirement System of Texas Purchases Shares of 10,219 Stoke Therapeutics, Inc. (NASDAQ:STOK)

Teacher Retirement System of Texas acquired a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,219 shares of the company’s stock, valued at approximately $113,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC raised its stake in Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after acquiring an additional 47,239 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after purchasing an additional 76,661 shares during the period. State Street Corp increased its holdings in shares of Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after purchasing an additional 137,145 shares during the period. RTW Investments LP raised its stake in shares of Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after purchasing an additional 427,447 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Stoke Therapeutics by 1,589.7% in the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after purchasing an additional 71,647 shares during the period.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have commented on STOK shares. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and set a $47.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of “Buy” and a consensus target price of $24.67.

Stoke Therapeutics Price Performance

Shares of STOK opened at $6.60 on Thursday. Stoke Therapeutics, Inc. has a 12-month low of $6.10 and a 12-month high of $17.58. The stock has a market capitalization of $356.91 million, a P/E ratio of -3.14 and a beta of 0.99. The firm’s 50 day moving average is $9.12 and its 200-day moving average is $10.99.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. As a group, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.